Objective. To 1) describe the distribution of patient global assessment (PtGA) scores of disease activity in patients with granulomatosis with polyangiitis (GPA; Wegener's), 2) explore the discordance between PtGA scores and physician global assessment (PhGA) scores of disease activity, and 3) explore whether PtGA scores during disease remission are associated with future disease relapse.
Granulomatosis with polyangiitis (GPA; Wegener's) is a multisystem disease that often has a chronic course with frequent periods of relapse and remission. Disease remission is attained for the great majority of patients, and longitudinal studies demonstrate that patients with GPA are in apparent remission at most study visits (1) (2) (3) (4) . The Birmingham Vasculitis Activity Score (BVAS) (5) and its modifications are the most widely accepted tools for disease activity assessment in antineutrophil cytoplasmic antibody-associated vasculitis, with remission usually defined as a BVAS score of 0. However, the BVAS is a purely physician-based disease measure that relies on the physician's judgment regarding involvement of individual organ systems and attribution of manifestations to disease activity but not to permanent damage, adverse effects from treatments, or other nonvasculitis disease processes. It is increasingly recognized that patients can provide insight to disease assessment beyond what can be obtained from physician-based disease assessments or laboratory values (6) (7) (8) .
The objectives of this study were to 1) describe the distribution of scores for patient global assessment (PtGA) of disease activity in patients with GPA enrolled in a clinical trial, 2) explore the discordance between PtGA scores and physician global assessment (PhGA) scores of disease activity, and 3) explore whether PtGA scores during disease remission are associated with future occurrence of disease relapse.
PATIENTS AND METHODS
Data source. Data from the Wegener's Granulomatosis Etanercept Trial (WGET) (1) (see Appendix A for a list of participating centers and investigators) were used. The WGET was a randomized, double-blind, placebo-controlled trial conducted at 8 clinical centers in North America, testing the addition of etanercept or placebo to standard remissioninduction therapy (glucocorticoids plus cyclophosphamide or methotrexate) for patients with GPA. Patients were enrolled at a time of active vasculitis and had study visits at baseline, 6 weeks, and every 3 months thereafter.
Study variables. PtGA scores of disease activity were assessed at every study visit, on a 100-mm visual analog scale (VAS) (scored 0-100), with the question, "Please mark the line below indicating how active you believe your Wegener's granulomatosis has been in the past 28 days. Consider only how much your Wegener's (the disease itself) is causing you problems. Do not count the effects of other medical problems or side effects of medications." PhGA scores of disease activity were assessed at every study visit, on a 100-mm VAS (scored 0-100), with the question, "Mark line to indicate the amount of WG disease activity (not including longstanding damage) within the previous 28 days. " Disease activity was assessed with the BVAS/WG (9). The BVAS/WG measures activity in 34 items, categorized into 9 groups. BVAS/WG values range from 0 to 63, with higher scores representing more manifestations of active disease. Active disease was defined as a BVAS/WG score of Ͼ0, and remission was defined as a BVAS score of 0. Disease relapse was defined as a BVAS/WG score of Ͼ0 when the BVAS/WG score had been 0 at the preceding study visit.
Renal disease and pulmonary disease were each defined on the basis of corresponding BVAS/WG items. Healthrelated quality of life (HRQOL) was assessed with the Short Form 36 (SF-36) health survey at the baseline visit. The SF-36 contains 36 items that assess HRQOL in 8 health dimensions: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health (10, 11) . Scores for each dimension/subscale range from 0 to 100, with higher scores indicating better HRQOL. Two summary scores are derived from the 8 subscales: the physical component summary score and the mental component summary score, both of which are norm-based scores standardized to the values for the US general population and transformed to have a mean of 50 and SD of 10 in the referent population.
PtGA-PhGA discordance was defined as a difference between the PtGA and PhGA scores (on 100-mm VAS) of Ն20 points. We also explored whether our findings were sensitive to discordance thresholds of Ն10 points or Ն30 points.
Statistical analysis. The distribution of outcome measures at baseline was expressed as the mean Ϯ SD. Pearson's correlation coefficients were calculated to determine the correlations between the global assessment scores and the SF-36 subscores. Logistic regression was used to explore the association of PtGA-PhGA discordance with age, sex, newly diagnosed disease or relapsing disease at baseline, and presence of renal or pulmonary disease. The association of the demographic and disease-associated factors with PtGA-PhGA discordance was expressed as the odds ratio (OR) with 95% confidence intervals (95% CIs).
To explore whether the PtGA score was increased prior to overt disease relapse, analysis was limited to data from visits during remission. Mixed linear models were used to explore differences in PtGA scores between study visits during remission but immediately prior to overt relapse, and other study visits during remission; random intercepts were included in the models to account for multiple observations from each subject. The difference in PtGA scores at visits prior to relapse compared to other remission visits was expressed as points on the VAS with 95% CIs. All statistical analyses were done using SAS version 9.2.
RESULTS

Patients.
One-hundred eighty patients participated in the WGET and were seen at a total of 1,719 study visits. At baseline, when all patients had active disease (mean Ϯ SD BVAS/WG score 7.0 Ϯ 3.4), the mean Ϯ SD PtGA score was 64.2 Ϯ 27.4, and the mean Ϯ SD PhGA score was 55.5 Ϯ 23.4. At study entry, 100 patients had relapsing disease and 80 patients had a new diagnosis of GPA. Renal involvement was present at baseline in 97 patients (54%), and pulmonary involvement was present at baseline in 108 patients (60%).
Correlations of measures at baseline. PtGA scores were modestly correlated with both PhGA scores (r ϭ 0.30, P Ͻ 0.0001) and BVAS/WG scores (r ϭ 0.28, P Ͻ 0.0001). PhGA scores were highly correlated with BVAS/WG scores (r ϭ 0.62, P Ͻ 0.0001). The PtGA score correlated weakly or moderately with all of the subscores of the SF-36; no correlation or much weaker correlations were observed between the PhGA score and SF-36 subscores (Table 1) .
Discordance between patient and physician global assessments at baseline. At baseline, there was substantial discordance regarding the assessment of dis-PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN GPA 429 ease activity between the patients and the physicians. For 95 patients (53%), there was a difference of at least 20 points between the PtGA and PhGA scores. Having newly diagnosed disease at study entry was inversely associated with PtGA-PhGA discordance (OR 0.37, 95% CI 0.20-0.68). This means that patients with newly diagnosed disease were more likely than those with relapsing disease to agree with the physician's global assessment of disease activity. This inverse association was not dependent on the defined threshold for PtGAPhGA discordance (Table 2) . No demographic or disease-related factor was significantly associated with the PtGA-PhGA discordance. Patient global assessment during remission and its association with future disease relapse. Of the 180 patients with GPA, 162 (90%) achieved disease remission (BVAS/WG score of 0) on at least one study visit. Among these 162 patients, 74 (46%) experienced at least one disease relapse. The 162 patients who achieved remission had a total of 1,058 visits during the times of remission, of which 103 visits were followed by a disease relapse. At visits immediately prior to relapse, the mean PtGA score was 4.52 points higher (95% CI 0.66-8.4) compared to that at other remission visits (P ϭ 0.03) ( Table 3) . Among the 74 patients who experienced disease relapse after achievement of remission, the PtGA score was 3.0 points higher (95% CI Ϫ1.68-7.76) at the visit immediately preceding relapse compared to that at other remission visits among this group (P ϭ 0.21).
DISCUSSION
This study demonstrates that a simple patientreported outcome, in this case a global score of disease activity measured by a 100-mm VAS, captures novel and important disease aspects in GPA. The PtGA only modestly correlates with other outcome measures, and patient and physician disease assessments were commonly discordant. Correlations between subscores of the SF-36 and the PtGA score were weak or modest, but statistically significant. These findings support several intriguing concepts: 1) the PtGA captures disease domains not assessed by physician-based measures; 2) The finding that, when compared to patients in the WGET trial with relapsing disease at baseline, patients with newly diagnosed GPA at the baseline visit were more likely to agree with their physician with respect to assessment of disease activity was unexpected. It is possible that disease assessment in cases of relapsing disease presents more complexities than that in newly presented cases, with a need by both physicians and patients to differentiate active disease from the effects of disease-or treatment-related damage.
This study has important strengths. The data source was a well-defined patient cohort with GPA, characterized by high disease activity at baseline, followed by disease remission in a majority of the patients, and then by 1 or more relapses in a substantial number of patients. The assessments were made prospectively per a clearly defined protocol at centers expert in the care of patients with GPA. The dynamics of disease trajectories seen in this cohort and comprehensive, repeated standardized disease assessments make this a rich data source for assessing the utility of outcome measures in GPA.
The study also has some limitations. Direct measures of fatigue, pain, dyspnea, and other important manifestations of disease from the patient perspective (12) were not collected. Although the observed measures of correlation between subscores of the SF-36 and the PtGA score suggest that fatigue (vitality) and social function might be the domains of HRQOL that contribute the most to the PtGA, individual subscores of the SF-36 did not have optimal distribution for such calculations, and therefore these results should be interpreted with caution. Further exploration of the dimensions of disease captured by the PtGA is much needed. Based on findings from the WGET, etanercept is generally considered inefficacious for the treatment of GPA. Therefore, data originating from the WGET would not allow assessment of how outcome measures discriminate between treatment arms. Consistent with the trial's primary conclusion, PtGA scores did not discriminate between treatment arms in this study (results not shown).
The utility of the PtGA should be explored further with respect to its construct validity with other disease manifestations and its ability to discriminate between treatment arms. It is likely that the PtGA could contribute to a composite measure of disease activity in GPA, as it has for other diseases (13, 14) , and could provide unique information complementary to standard physician assessments. In the absence of tools better than those currently available for assessment of disease activity in GPA, data obtained through the use of this highly feasible patient-reported outcome should be collected in all longitudinal studies of GPA, especially in randomized controlled trials of therapies in GPA.
